Entrada Therapeutics, Inc.
- TRDA
- NASDAQ
- Biotechnology
- Neuromuscular Therapies
- EEV Drug Delivery Platform
- Biotech
$4.82
Today +10.30%Quote Oct 19, 2026, 08:00 PM UTC
−28.59%over the last month
Max drawdown −35.3%From 1-month high −28.6%3 months −25.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Entrada Therapeutics
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
152
Founded
2016
Market value
$187.7M
Quote Oct 19
Floor
$4.72
2.0% below price
Resistance
$5.34
10.7% above price
Price vs analyst targets
6 analysts
Lowest target
$11.00Highest target
$17.00
$11.00Highest target
$17.00
- Price $4.82
- Average target $14.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 190% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TRDAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free